SCHEMBL19984728

SCHEMBL19984728

CC(C)(C)OC(=O)NCc1cnc(C2=CC(=O)CC2)s1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.35
CA1 P00915 3/20 0.34
CA2 P00918 3/20 0.34
CA9 Q16790 3/20 0.34
CA12 O43570 2/20 0.34
FPR3 P25089 2/20 0.34
FPR2 P25090 2/20 0.34
GAA P10253 1/20 0.34
NAMPT P43490 2/20 0.34
HDAC3 O15379 1/20 0.34
HDAC4 P56524 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC7 Q8WUI4 1/20 0.34
HDAC2 Q92769 1/20 0.34
HDAC10 Q969S8 1/20 0.34
HDAC11 Q96DB2 1/20 0.34
HDAC8 Q9BY41 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
HDAC9 Q9UKV0 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18667622 0.84 L3MBTL1 (0.42) DYRK1AL3MBTL1CA1CA2CA9
SCHEMBL26759908 0.79 L3MBTL1 (0.39) DYRK1AL3MBTL1CA1CA2CA9
SCHEMBL18667424 0.79 PPARA (0.47) DYRK1AL3MBTL1CA1CA12NAMPT
SCHEMBL18667080 0.78 DYRK1A (0.52) DYRK1AL3MBTL1HDAC3HDAC4HDAC1
SCHEMBL18667055 0.78 HDAC1 (0.43) DYRK1AL3MBTL1NAMPTHDAC3HDAC4
SCHEMBL18641422 0.77 ALDH1A1 (0.43) DYRK1AL3MBTL1GAANAMPTHDAC3
SCHEMBL18667640 0.77 HDAC1 (0.43) DYRK1AL3MBTL1NAMPTHDAC3HDAC4
SCHEMBL18667556 0.77 HDAC1 (0.45) DYRK1AL3MBTL1FPR3FPR2NAMPT
SCHEMBL18667382 0.77 GRM2 (0.47) DYRK1AL3MBTL1GAANAMPTHDAC3
SCHEMBL23185423 0.75 DYRK1A (0.45) DYRK1AL3MBTL1CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220023311-A1 HEPATITIS B CORE PROTEIN MODULATORS ASSEMBLY BIOSCIENCES INC (US) 2022-01-27 US disclosed
US-10987360-B2 Hepatitis B core protein modulators ASSEMBLY BIOSCIENCES, INC. (US) 2021-04-27 US disclosed
US-20190255067-A1 HEPATITIS B CORE PROTEIN MODULATORS ASSEMBLY BIOSCIENCES INC (US) 2019-08-22 US disclosed
WO-2018053157-A1 HEPATITIS B CORE PROTEIN MODULATORS ASSEMBLY BIOSCIENCES, INC. (US) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10987360-B2 Hepatitis B core protein modulators HAVCR2, FABP1, MAVS DYRK1A 4398/4885L3MBTL1 2994/4885CA1 4734/4885
US-20190255067-A1 HEPATITIS B CORE PROTEIN MODULATORS HAVCR2, FABP1, MAVS DYRK1A 4398/4885L3MBTL1 2994/4885CA1 4734/4885
US-20220023311-A1 HEPATITIS B CORE PROTEIN MODULATORS HAVCR2, FABP1, MAVS DYRK1A 4398/4885L3MBTL1 2994/4885CA1 4734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.